BioCatalystWatch
BYSIWorkspace / BYSI / OverviewCompany library
Price
Market cap
Next catalystExpected 2H 2026ST-01156 · Phase 1 dataCompany presentation ↗
Cash

Chart & Events

Candle interval

Core Clinical

ST-01156

RBM39

PreINDP1P2P3FilingApproved
Upcoming / outlook

ST-01156

RBM39

Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

ST-01156

RBM39

PreINDP1P2P3FilingApproved
Upcoming / outlook

ST-01156

RBM39

Upcoming / outlook

Other pipelines

Plinabulin

β-tubulin

PreINDP1P2P3FilingApproved
Plinabulin

β-tubulin

PreINDP1P2FilingApproved
Upcoming / outlook

  • Timing and evidence

BPI-002

BPI-004

PreINDP1P2P3FilingApproved
BPI-003

IKK

PreINDP1P2P3FilingApproved
ST-01156

RBM39

PreINDP1P2P3FilingApproved

History / paused

Plinabulin

β-tubulin

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

BYSI PR & News

PR & News

BeyondSpring Inc.
Plinabulin

BYSI SEC archive